摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-amino-1-cyanomethyl-1,2,3,4-tetrahydronaphthalene | 887753-48-2

中文名称
——
中文别名
——
英文名称
3-amino-1-cyanomethyl-1,2,3,4-tetrahydronaphthalene
英文别名
2-(3-Amino-1,2,3,4-tetrahydronaphthalen-1-yl)acetonitrile
3-amino-1-cyanomethyl-1,2,3,4-tetrahydronaphthalene化学式
CAS
887753-48-2
化学式
C12H14N2
mdl
——
分子量
186.257
InChiKey
UXPDGQWIEXMUAZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    363.3±35.0 °C(Predicted)
  • 密度:
    1.065±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.2
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    49.8
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    3-amino-1-cyanomethyl-1,2,3,4-tetrahydronaphthalene5-氯吲哚-2-羧酸1-羟基苯并三唑盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺N,N-二异丙基乙胺 作用下, 以 四氢呋喃 为溶剂, 反应 0.75h, 生成 5-chloro-N-[(4S)-4-(cyanomethyl)-1,2,3,4-tetrahydronaphthalen-2-yl]-1H-indole-2-carboxamide
    参考文献:
    名称:
    2-Amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
    摘要:
    提供了一些新的化合物,它们是糖原磷酸化酶抑制剂,可用于治疗、预防或减缓需要糖原磷酸化酶抑制剂治疗的疾病,如糖尿病及相关疾病(如高血糖、糖耐量受损、胰岛素抵抗和高胰岛素血症),与糖尿病相关的微血管并发症(如视网膜病变、神经病变、肾病和延迟伤口愈合),与糖尿病相关的大血管并发症(心血管疾病,如动脉粥样硬化、心脏功能异常、心肌缺血和中风),以及代谢综合征及其组成疾病,包括高血压、肥胖和脂质代谢异常(包括高三酸甘油酯血症、高胆固醇血症和低高密度脂蛋白血症),以及其他疾病,如非心脏缺血、感染和癌症。这些新的化合物具有特定的结构、立体异构体、前药或其药用可接受的盐,其中W、R1、R2、X和Z在此处有定义。
    公开号:
    US20060111338A1
  • 作为产物:
    描述:
    3-Benzyloxycarbonylamino-1-cyanomethylene-1,2,3,4-tetrahydronaphthalene 在 palladium 10% on activated carbon 氢气 作用下, 以 乙醇 为溶剂, 反应 24.17h, 生成 3-amino-1-cyanomethyl-1,2,3,4-tetrahydronaphthalene 、 ethyl 2-[(1R,3R)-3-[(5-chloro-1H-indole-2-carbonyl)amino]-1,2,3,4-tetrahydronaphthalen-1-yl]acetate
    参考文献:
    名称:
    2-Amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
    摘要:
    提供了一些新的化合物,它们是糖原磷酸化酶抑制剂,可用于治疗、预防或减缓需要糖原磷酸化酶抑制剂治疗的疾病,如糖尿病及相关疾病(如高血糖、糖耐量受损、胰岛素抵抗和高胰岛素血症),与糖尿病相关的微血管并发症(如视网膜病变、神经病变、肾病和延迟伤口愈合),与糖尿病相关的大血管并发症(心血管疾病,如动脉粥样硬化、心脏功能异常、心肌缺血和中风),以及代谢综合征及其组成疾病,包括高血压、肥胖和脂质代谢异常(包括高三酸甘油酯血症、高胆固醇血症和低高密度脂蛋白血症),以及其他疾病,如非心脏缺血、感染和癌症。这些新的化合物具有特定的结构、立体异构体、前药或其药用可接受的盐,其中W、R1、R2、X和Z在此处有定义。
    公开号:
    US20060111338A1
点击查看最新优质反应信息

文献信息

  • Multiple catalyst system for olefin polymerization and polymers produced therefrom
    申请人:Jiang Peijun
    公开号:US20070293640A1
    公开(公告)日:2007-12-20
    This invention relates to a polymer comprising one or more C3 to C40 olefins, optionally one or more diolefins, and less than 15 mole % of ethylene, where the polymer has: a) a Dot T-Peel of 1 Newton or more; and b) a branching index (g′) of 0.95 or less measured at the Mz of the polymer; c) an Mw of 100,000 or less. This invention also relates a polymer comprising one or more C3 to C40 olefins where the polymer has: a) a Dot T-Peel of 1 Newton or more on Kraft paper; b) a branching index (g′) of 0.95 or less measured at the Mz of the polymer; c) a Mw of 10,000 to 100,000; and d) a heat of fusion of 1 to 70 J/g. This invention also relates a polymer comprising one or more C3 to C40 olefins where the polymer has: a) a Dot T-Peel of 1 Newton or more on Kraft paper; b) a branching index (g′) of 0.98 or less measured at the Mz of the polymer; c) a Mw of 10,000 to 60,000; d) a heat of fusion of 1 to 50 J/g. This invention also relates to a homopolypropylene or a copolymer of propylene and up to 5 mole % ethylene having: a) an isotactic run length of 1 to 30 (isotactic run length “IRL” is defined to be the percent of mmmm pentad divided by 0.5× percent of mmmr pentad) as determined by Carbon 13 NMR, preferably 3 to 25, more preferably 4 to 20, b) a percent of r dyad of greater than 20%, preferably from 20 to 70% as determined by Carbon 13 NMR, and c) a heat of fusion of 70 J/g or less, preferably 60 J/g or less, more preferably between 1 and 55 J/g, more preferably between 4 and 50 J/g. This invention further relates to a process to produce an olefin polymer comprising: 1) selecting a first catalyst component capable of producing a polymer having an Mw of 100,000 or less and a crystallinity of 5% or less at selected polymerization conditions; 2) selecting a second catalyst component capable of producing polymer having an Mw of 100,000 or less and a crystallinity of 20% or more at the selected polymerization conditions; 3) contacting the catalyst components in the presence of one or more activators with one or more C3 to C40 olefins, at the selected polymerization conditions in a reaction zone; 4) obtaining the polymer. This invention further relates to a continuous process to produce a branched olefin polymer comprising: 1) selecting a first catalyst component capable of producing a polymer having an Mw of 100,000 or less and a crystallinity of 5% or less under selected polymerization conditions; 2) selecting a second catalyst component capable of producing polymer having an Mw of 100,000 or less and a crystallinity of 20% or more at the selected polymerization conditions; 3) contacting the catalyst components in the presence of one or more activators with one or more C3 to C40 olefins, and, optionally one or more diolefins; 4) at a temperature of greater than 100° C.; 5) at a residence time of 120 minutes or less; 6) wherein the ratio of the first catalyst to the second catalyst is from 1:1 to 50:1; 7) wherein the activity of the catalyst components is at least 100 kilograms of polymer per gram of the catalyst components; and wherein at least 20% of the olefins are converted to polymer.
  • US7226942B2
    申请人:——
    公开号:US7226942B2
    公开(公告)日:2007-06-05
  • [EN] 2-AMINO-4-FUNCTIONALIZED TETRALIN DERIVATIVES AND RELATED GLYCOGEN PHOSPHORYLASE INHIBITORS<br/>[FR] DERIVES 2-AMINO-4- TETRALINE FONCTIONNALISEE ET INHIBITEURS DE LA GLYCOGENE PHOSPHORYLASE ASSOCIES
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2006055462A1
    公开(公告)日:2006-05-26
    [EN] Novel compounds are provided which are glycogen phosphorylase inhibitors which are useful in treating, preventing or slowing the progression of diseases requiring glycogen phosphorylase inhibitor therapy such as diabetes and related conditions (such as hyperglycemia, impaired glucose tolerance, insulin resistance and hyperinsulinemia), the microvascular complications associated with diabetes (such as retinopathy, neuropathy, nephropathy and delayed wound healing), the macrovascular complications associated with diabetes (cardiovascular diseases such as atherosclerosis, abnormal heart function, myocardial ischemia and stroke), as well as Metabolic Syndrome and its component conditions including hypertension, obesity and dislipidemia (including hypertriglyceridemia, hypercholesterolemia and low HDL), and other maladies such as non-cardiac ischemia, infection and cancer. These novel compounds have the structure [INSERT CHEMICAL STRUCTURE HERE] I or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W, R1, R2, X and Z are defined herein.
    [FR] L'invention concerne de nouveaux composés inhibiteurs de la glycogène phosphorylase utiles dans le traitement, la prévention ou le ralentissement de l'évolution de maladies nécessitant une thérapie par inhibiteur de la glycogène phosphorylase, telles que les diabète et des affections associées (telles que l'hyperglycémie, l'altération de la tolérance au glucose, la résistance à l'insuline et l'hyperinsulinémie), les complications microvasculaires associées au diabète (telles que la rétinopathie, la neuropathie, la néphropathie et une cicatrisation retardée), les complications macrovasculaires associées au diabète (maladies cardiovasculaires, telles que l'athérosclérose, une fonction cardiaque anormale, l'ischémie myocardique et l'accident cérébrovasculaire) ainsi que le syndrome métabolique et ses composantes comprenant l'hypertension, l'obésité et la dislipidémie (y compris l'hypertriglycéridémie, l'hypercholestérolémie et une HDL faible) et d'autres maladies telles que l'ischémie non cardiaque, l'infection et le cancer. Ces nouveaux composés ont la structure de formule (I). L'invention se rapporte également à des stéréoisomères ou des promédicaments ou leurs sels pharmaceutiquement acceptables, où W, R1, R2, X et Z sont définis.
  • 2-Amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
    申请人:Sher M. Philip
    公开号:US20060111338A1
    公开(公告)日:2006-05-25
    Novel compounds are provided which are glycogen phosphorylase inhibitors which are useful in treating, preventing or slowing the progression of diseases requiring glycogen phosphorylase inhibitor therapy such as diabetes and related conditions (such as hyperglycemia, impaired glucose tolerance, insulin resistance and hyperinsulinemia), the microvascular complications associated with diabetes (such as retinopathy, neuropathy, nephropathy and delayed wound healing), the macrovascular complications associated with diabetes (cardiovascular diseases such as atherosclerosis, abnormal heart function, myocardial ischemia and stroke), as well as Metabolic Syndrome and its component conditions including hypertension, obesity and dislipidemia (including hypertriglyceridemia, hypercholesterolemia and low HDL), and other maladies such as non-cardiac ischemia, infection and cancer. These novel compounds have the structure or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W, R 1 , R 2 , X and Z are defined herein.
    提供了一些新的化合物,它们是糖原磷酸化酶抑制剂,可用于治疗、预防或减缓需要糖原磷酸化酶抑制剂治疗的疾病,如糖尿病及相关疾病(如高血糖、糖耐量受损、胰岛素抵抗和高胰岛素血症),与糖尿病相关的微血管并发症(如视网膜病变、神经病变、肾病和延迟伤口愈合),与糖尿病相关的大血管并发症(心血管疾病,如动脉粥样硬化、心脏功能异常、心肌缺血和中风),以及代谢综合征及其组成疾病,包括高血压、肥胖和脂质代谢异常(包括高三酸甘油酯血症、高胆固醇血症和低高密度脂蛋白血症),以及其他疾病,如非心脏缺血、感染和癌症。这些新的化合物具有特定的结构、立体异构体、前药或其药用可接受的盐,其中W、R1、R2、X和Z在此处有定义。
查看更多

同类化合物

(S)-(+)-5,5'',6,6'',7,7'',8,8''-八氢-3,3''-二叔丁基-1,1''-二-2-萘酚,双钾盐 顺式-4-(4-氯苯基)-1,2,3,4-四氢-N-甲基-1-萘胺盐酸盐 顺式-4-(3,4-二氯苯基)-1,2,3,4-四氢N-叔丁氧羰基-1-萘胺 顺式-1-苯甲酰氧基-2-二甲基氨基-1,2,3,4-四氢萘 顺式-1,2,3,4-四氢-5-环氧丙氧基-2,3-萘二醇 顺式-(1S,4S)-N-甲基-4-(3,4-二氯苯基)-1,2,3,4-四氢-1-萘胺扁桃酸盐 顺-5,6,7,8-四氢-6,7-二羟基-1-萘酚 顺-(+)-5-甲氧基-1-甲基-2-(二正丙基氨基)萘满马来酸 阿洛米酮 阿戈美拉汀杂质醇(A) 阿戈美拉汀杂质 钠2-羟基-7-甲氧基-1,2,3,4-四氢-2-萘磺酸酯 金钟醇 邻烯丙基苯基溴化镁 那高利特盐酸盐 那高利特 过氧化,1,1-二甲基乙基1,2,3,4-四氢-1-萘基 贝多拉君 螺<4.7>十二烷 蔡醇酮 萘磺酸,二癸基-1,2,3,4-四氢- 萘并[2,3-d]咪唑,2-乙基-5,6,7,8-四氢-(6CI) 萘亚胺 苯甲酸-(5,6,7,8-四氢-[2]萘基酯) 苯甲丁氮酮 苯甲丁氮酮 苯甲丁氮酮 苯并烯氟菌唑 舍曲林二甲基杂质盐酸盐 舍曲林EP杂质B 舍曲林 羟甲基四氢萘酚 美曲唑啉 罗替戈汀硫酸盐 罗替戈汀杂质18 罗替戈汀中间体 罗替戈汀中间体 罗替戈汀 罗替戈汀 纳多洛尔杂质 米贝地尔(二盐酸盐) 盐酸舍曲林 盐酸舍曲林 盐酸罗替戈汀 盐酸左布诺洛尔 盐酸四氢唑林 甲基缩合物 甲基6-[1-(3,5,5,8,8-五甲基-5,6,7,8-四氢-2-萘基)环丙基]烟酸酯 甲基-(2-吡咯烷-1-基甲基-1,2,3,4-四氢-萘-2-基)-胺 环丙烯并[a]茚,1-溴-1-氟-1,1a,6,6a-四氢-